Iovance Biotherapeutics, Inc.

    Jurisdiction
    United States
    LEI
    2549002L8WT2ACU5Q878
    ISIN
    US4622601007 (IOVA)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Read full profile

    Fundamentals

    Net revenue
    €206.01M
    Gross margin
    20.6%
    EBIT
    -€350.25M
    EBIT margin
    -170.0%
    Net income
    -€332.58M
    Net margin
    -161.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €366.57M +77.9% N/A
    €528.60M +44.2% N/A
    €684.65M +29.5% N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 3.5M $11.69M +2.3M Buy

    Earnings Calls

    Latest earnings call: May 9, 2024 (Q1 2024)

    Add to watchlist

    Notifications